Harrow signs definitive deal to acquire Melt Pharma for initial $4.3M plus milestones up to ~$352.5M

HARROW, INC.

Initial cash payment of ~$4.3M for remaining 55% equity; contingent $87.2M upon FDA approval of MELT-300.
Upon CMS J-Code assignment, Harrow will issue ~1.112M shares of common stock.
Additional cash payments up to ~$261M based on annual net sales milestones ($100M–$1B).
Harrow plans NDA submission in 2027, potential US launch in 2028 for MELT-300 sublingual sedation.
Deal approved by independent committee; fairness opinion from Lake Street Capital Markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.